Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 3,324 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Diseases Clear all
Completed Phase 1 Interventional

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

NCT01041235
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
Interventions
ATI-1123 (active drug = docetaxel)
Drug
Lead sponsor
Azaya Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 17, 2026, 9:08 PM EDT
Recruiting Phase 1 Interventional

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

NCT05372614
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Neratinib Maleate, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Lancaster, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

NCT02362048
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
ACP-196, ACP-196 in combination with pembrolizumab
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 17, 2026, 9:08 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

NCT06544655
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

NCT04064034
View directory record Official record
Conditions
Pancreas Cancer, Pancreas Cyst
Interventions
Lateral Flow Assay (LFA)
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
17 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 17, 2026, 9:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

NCT07539155
View directory record Official record
Conditions
Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Interventions
Intratumoral MMR Injection
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 9:08 PM EDT
Not listed Phase 1 Interventional

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

NCT02950064
View directory record Official record
Conditions
Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
BTP-114
Drug
Lead sponsor
Placon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

NCT01360593
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Capecitabine, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
David A. Clump, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Not applicable Interventional Results available

Early Intervention in Cystic Fibrosis Exacerbation

NCT01104402
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Home lung function and symptom monitoring
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 17, 2026, 9:08 PM EDT
Recruiting No phase listed Observational

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

NCT02674100
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Registry
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Results available

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

NCT00836407
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Ipilimumab, Pancreatic Cancer Vaccine
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 17, 2026, 9:08 PM EDT
Withdrawn Phase 2 Interventional

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT04130399
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX
Radiation · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study to Assess Safety and Efficacy of ANG003

NCT06052293
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
ANG003
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Not applicable Interventional

Vitamin D and Microbiota in Cystic Fibrosis

NCT02589444
View directory record Official record
Conditions
Vitamin D Deficiency, Cystic Fibrosis
Interventions
High-Dose Vitamin D3, Stool Sample, Sputum Sample, Sham Comparator, Blood draw
Dietary Supplement · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

NCT02565914
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 1 Interventional

CART-meso in Mesothelin Expressing Cancers

NCT02159716
View directory record Official record
Conditions
Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer, Malignant Epithelial Pleural Mesothelioma
Interventions
CART-meso
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 17, 2026, 9:08 PM EDT
Recruiting Not applicable Interventional

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

NCT05053555
View directory record Official record
Conditions
Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
Interventions
high dose rate brachytherapy
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Not applicable Interventional

Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer

NCT01356030
View directory record Official record
Conditions
Pancreaticobiliary Cancers, Jaundice, Bile Duct Obstruction
Interventions
ERCP, EUS FNA
Procedure
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 17, 2026, 9:08 PM EDT
Not listed Not applicable Interventional

Remote Monitoring of High-Risk Patients With Chronic Cardiopulmonary Diseases

NCT04825067
View directory record Official record
Conditions
Congestive Heart Failure, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis
Interventions
Respiratory Sensor measurements
Device
Lead sponsor
Institute of Bioengineering and Bioimaging (IBB)
Government
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

NCT00506792
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
QAU145, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

NCT00559364
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Pancreatectomy
Interventions
Viokase® 16, Placebo, Proton pump inhibitor (PPI), Omeprazole
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

NCT02632448
View directory record Official record
Conditions
Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Interventions
LY2880070, Gemcitabine
Drug
Lead sponsor
Esperas Pharma Inc.
Other
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 17, 2026, 9:08 PM EDT
Completed Phase 2 Interventional

Preop Chemoradiation Resectable Pancreas

NCT00336648
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Avastin (Bevacizumab), Gemcitabine, Radiation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 17, 2026, 9:08 PM EDT